Avid Bioservices Inc (CDMO)

[biopharm]

That he is that Garnick fellow:.."he sees promise in both bavituximab and Peregrine’s other drug candidate, Cotara for brain cancer. Cotara is being studied for the treatment of gliboblastoma multiforme, or GBM."

In my opinion.... there is no other man qualified to tell Peregrine that Bavi works better than Avastin than the man (Garnick) who walked Avastin in the doors of the FDA and out with its 1st approval.

IMHO....Peregrine has been pitted up against Avastin for months and Garnick is weeks away from entering the FDA again and exiting with Bavi's 1st approval.